Listen to this page using ReadSpeaker

ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial

ProQR, a biotech company in the Netherlands, has treated its first patient in a Phase 1/2 clinical trial for QR-110, a therapy for people with Leber congenital amaurosis 10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world.

The Phase 1/2 trial will enroll six children and six adults who have the mutation. Participants will receive a dose in one eye every three months for a year. The treatment is delivered through an injection into the vitreous, the gel-like substance in the middle of the eye.

The company plans to report interim, six-month study results in 2018 and 12-month results in 2019. The trial is taking place at the Scheie Eye Institute at the University of Pennsylvania in Philadelphia, the University of Iowa in Iowa City, and Ghent University Hospital in Belgium.

Known as an antisense oligonucleotide (AON), QR-110 is a drug that works like “genetic tape” to repair the mutation. Unlike gene replacement therapies in which copies of whole genes are delivered to replace defective copies, AONs correct the mutation in the patient’s messenger RNA, which conveys genetic information for protein production. AONs can be advantageous when large retinal-disease genes — such as CEP290 or USH2A — exceed the capacity of viral gene-replacement delivery systems.

“We are very excited to see this trial get off the ground,” says Stephen Rose, PhD, chief research officer, Foundation Fighting Blindness. “ProQR’s groundbreaking therapy provides hope for saving and restoring vision for people with a condition that causes devastating vision loss.”

ProQR is also working toward clinical trials for Usher syndrome type 2A (USH2A) and Stargardt disease therapies. Its two emerging USH2A treatments repair the c.7595-2144A>G mutation and mutations in a genetic region known as exon 13.

6 Responses to 'ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial'

  1. Fatimah Badru says:

    Pls I am from Nigeria. It’s possible for my son and daughter of 6months take place in this trial. I will be very happy if something can be done.They are suffering from Leiber congenital amurosis. Thanks

  2. M. MEFTAH says:

    my 12 year old child affected by LCA which TULP1 is the gene mutated cause.
    my question is “if the trial is successful, it can b treat the eyes of my child”.

    • EyeOnTheCure says:

      Your child has a different mutated gene, so this project is not directed at your child’s condition. Other emerging therapies may be relevant including stem cells which work independent of the mutated gene.

  3. Eric Hattan says:

    Is this for everyone with Leber’s congenital amaurosis or are there different types and this is only for one type?

    • EyeOnTheCure says:

      Hi Eric, this trial is for people with LCA caused by a specific mutation in the gene CEP290. This is only one type of LCA.

Leave a Reply

Your email address will not be published. Required fields are marked *